Indiana’s Only Federally Recognized Hemophilia Treatment CenterPaving the way in clinical research

Innovative Hematology helps bring improved therapies to market while providing opportunities for patients to contribute to the advancement of care and treatment.

Clinical research can improve overall understanding of bleeding and clotting disorders, increase knowledge of genetics, and provide ongoing safety information of therapy. Clinical research studies may offer patients and payors substantial new treatment options and cost savings related to laboratory testing. Cost savings are attributable to no cost while on a study drug, as well as lab tests associated with these studies.

Innovative Hematology has a long-standing history of leadership in clinical research, with numerous active studies available to eligible patients. Our organization performed the world’s first human infusion on the following products:

  • Genetically engineered factor IX concentrate 
  • Long-acting genetically engineered immunoglobulin fused factor IX concentrate 
  • Genetically engineered von Willebrand factor concentrate 
  • Genetically engineered bio-similar factor IX concentrate 
  • Intravenous Plasminogen (Human) Concentrate 

Innovative Hematology independently evaluates each study, weighing above all the project’s safety as well as the potential impact on future care. We coordinate a wide range of clinical research including pharmaceutical, observational, investigator-initiated, quality-of-life analyses, and nationally funded studies (e.g., Centers for Disease Control and Prevention, and National Institutes of Health).

Innovative Hematology clinical research coordinators connect patients to available studies and provide ongoing follow-up and coordination for the duration of their study participation.